News

Nourianz Reduces Duration of ‘Off Periods’ in Parkinson’s Patients with and without Dyskinesia, Analysis Finds

When used as an add-on treatment to carbidopa-levodopa, Nourianz (istradefylline) reduced the duration of “off periods” — when symptoms are not adequately controlled — and increased the duration of “on periods” in Parkinson’s disease patients with and without pre-existing dyskinesia, a pooled analysis of several clinical trials…

MJFF Offering Webinar Series for Scientists and Clinicians

The Michael J. Fox Foundation (MJFF) is offering a new online Parkinson’s disease educational series aimed at researchers and clinicians. Parkinson’s Disease Therapeutics Webinars, a free four-part series, starts June 16 and will feature presentations by leaders in Parkinson’s research and treatment development. “We know people with…

FDA Approves Kynmobi Sublingual Film to Treat Off Episodes in Parkinson’s

The U.S. Food and Drug Administration has approved Sunovion’s Kynmobi (apomorphine hydrochloride) as an on-demand sublingual treatment for off episodes, or times when medication wears off, in people with Parkinson’s disease. The medication, formerly known as APL-130277, is an apomorphine film that is placed under-the-tongue (sublingual administration) when…